CrystalGenomics Reports Positive Top-Line Data from Phase 2a Study of CG400549 in Patients with Complicated Acute Bacterial Skin and Skin Structure Infections Caused by MRSA
1/7/2013 11:19:30 AM
More...
|
Sigma-Aldrich Corporation (SIAL) Release: SAFC Enters South Korean BioPharma Market With CrystalGenomics Agreement
10/30/2012 9:35:29 AM
More...
|
CrystalGenomics Announces Positive Results from Phase 2b Osteoarthritis Study of CG100649
4/19/2012 9:45:26 AM
More...
|
CrystalGenomics Initiates CG100649 Phase 2b Study in Patients with Osteoarthritis
6/1/2011 9:32:28 AM
More...
|
CrystalGenomics Completes Phase I MAD Study of its Novel Antibiotic Candidate CG400549, and Prepares for Phase II Clinical Study
5/12/2011 7:23:46 AM
More...
|
CrystalGenomics to Present Preliminary Results from Recently Completed Supra-threshold Phase I MAD Study for CG100649, its Novel NSAID Candidate at the Arrowhead 4th Annual Pain Therapeutics Summit
10/4/2010 7:23:24 AM
More...
|
CrystalGenomics Nominated for the Scrip Award in the Category of Best Company in an Emerging Market
9/14/2010 1:36:39 PM
More...
|
CrystalGenomics Announces a Merger with BexPharm Pharmaceuticals Inc. and Emerges as an Integrated Biopharmaceutical Company
5/28/2010 9:27:36 AM
More...
|
CrystalGenomics Announces Successful Completion of a Phase I SAD Clinical Trial for CG400549, its Novel Antibiotic Candidate
5/11/2010 10:06:30 AM
More...
|
AstraZeneca PLC (AZN) and CrystalGenomics Form Research Collaboration to Develop Novel Anti-Infective Treatments
1/13/2010 11:55:50 AM
More...
|
|